Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
MWN-AI** Summary
Eledon Pharmaceuticals presented promising long-term data from its Phase 1b trial of tegoprubart, an investigational anti-CD40L antibody, during the American Society of Transplant Surgeons Winter Symposium in Scottsdale, Arizona, from January 23-25, 2026. The data encompasses a 24-month follow-up involving eight kidney transplant patients who showed significant improvements in kidney function and a favorable safety profile.
Key findings from the study reveal a notable increase in mean estimated glomerular filtration rate (eGFR) from 67.0 mL/min/1.73 m² at the 12-month mark to 74.2 mL/min/1.73 m² at 24 months, indicating enhanced renal function over time. Importantly, there were no reported incidents of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or the formation of de novo donor-specific antibodies throughout the study duration.
Eledon’s presentation is titled "Long-Term Outcomes of a Phase 1, Single Arm Cohort of De Novo Kidney Transplant Recipients Treated with Tegoprubart, an Anti-CD40L Antibody, as the Core Immunosuppression Regimen," which was showcased in Poster Session B on January 23. After the session, the presentation poster will be available on the Investors section of Eledon’s website.
As a clinical-stage biotechnology company based in Irvine, California, Eledon Pharmaceuticals is focused on developing immune-modulating therapies for serious health conditions, with tegoprubart as its leading candidate. The company emphasizes the significant therapeutic potential of targeting CD40L signaling pathways due to their vital role in immune cell function.
Overall, the data presented marks a critical step in exploring novel immunosuppressive strategies in kidney transplantation, underscoring Eledon’s commitment to advancing treatment options in this field.
MWN-AI** Analysis
Eledon Pharmaceuticals (Nasdaq: ELDN) has recently presented 24-month follow-up data from patients in its Phase 1b trial evaluating tegoprubart for kidney transplantation, highlighting a compelling safety profile and promising efficacy data. The increase in mean estimated glomerular filtration rate (eGFR) from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months indicates a potential improvement in kidney function among participants. Notably, the absence of acute rejection episodes and other adverse clinical events suggests that tegoprubart may represent a significant advancement in immunosuppressive therapy.
Given these developments, Eledon Pharmaceuticals is at a critical juncture. Investors should consider the implications of these results within the broader context of the biotechnology sector. Positive clinical data can catalyze investor sentiment and drive stock prices, especially given the unique therapeutic potential of tegoprubart as a non-lymphocyte depleting agent targeting CD40L. However, investors must also remain cognizant of the inherent risks associated with clinical-stage biotechnology stocks, particularly regarding funding needs and regulatory approvals.
As the market absorbs this data, the immediate reaction may lead to heightened volatility. Long-term investors may find value in accumulating shares, provided they are comfortable with the potential risks associated with biotechnology investments, such as clinical trial delays and competition. On the other hand, short-term traders might consider monitoring market reactions closely for profit-taking opportunities as enthusiasm builds or wanes.
In summary, while Eledon Pharmaceuticals shows promising signs with its tegoprubart data, prudent investors should balance the optimism around this clinical trial with an awareness of the broader risks in both the company’s pipeline and the pharmaceutical industry.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Data from eight participants continue to support safety and tolerability profile of tegoprubart
Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months
IRVINE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons Winter Symposium, taking place January 23–25, 2026, in Scottsdale, Arizona.
There were no episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de novo donor-specific antibody formation during the study period. Mean estimated glomerular filtration rate (eGFR) increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months.
Details on the poster presentation are below:
Title: Long-Term Outcomes of a Phase 1, Single Arm Cohort of De Novo Kidney Transplant Recipients Treated with Tegoprubart, an Anti-CD40L Antibody, as the Core Immunosuppression Regimen
Poster: #62
Session Title: Poster Session B
Date: Friday, January 23, 2026, from 5:45 - 7:15 p.m. PT
Following the presentation, a copy of the poster will be available in the Investors section of the Company’s website at https://ir.eledon.com/news-and-events/publications-and-presentations.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: our short operating history and shifts in our business strategy; our operating losses since inception; our need for additional funding to develop our lead drug candidate and our ability to secure additional funding on acceptable terms or at all; the impact of issuances of our common stock, including in the possibility of dilution or a decline in our stock price; our ability to successfully develop our product candidates; unfavorable global economic and financial market conditions; the regulatory environment of our business and our ability to obtain required regulatory approvals; results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials; delays or difficulties in enrollment of patients in clinical trials; our ability to attract and retain our executives and key employees; legislation of the pharmaceutical and healthcare industries; cybersecurity and data privacy risks; the ability of our products to achieve marketing approval; competition in our industry; our ability to obtain insurance coverage; our dependence on contract research organizations; our ability to protect our intellectual property; public health crises; our ability to establish and maintain proper and effective internal control over financial reporting and other risks disclosed in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Securities and Exchange Commission on November 14, 2025. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ materially from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
[email protected]
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
[email protected]
Source: Eledon Pharmaceuticals
FAQ**
What implications does the increase in mean eGFR from 67.0 mL/min/1.73 m² at months to 74.2 mL/min/1.73 m² at 24 months have for the potential long-term efficacy of Eledon Pharmaceuticals Inc Com ELDN in kidney transplantation?
Given the absence of adverse events such as acute rejection or new-onset diabetes, how does this safety profile of tegoprubart support Eledon Pharmaceuticals Inc Com ELDN's strategy for future clinical trials in transplantation?
What are the next steps Eledon Pharmaceuticals Inc Com ELDN plans to take following the promising 24-month data presentation at the American Society of Transplant Surgeons Winter Symposium?
How does Eledon Pharmaceuticals Inc Com ELDN plan to address the uncertainties outlined in their forward-looking statements as they advance tegoprubart in kidney transplantation and other therapeutic areas?
**MWN-AI FAQ is based on asking OpenAI questions about Eledon Pharmaceuticals Inc Com (NASDAQ: ELDN).
NASDAQ: ELDN
ELDN Trading
9.89% G/L:
$2.61 Last:
610,389 Volume:
$2.48 Open:
